Prostate cancer is a type of cancer that affects a lot of men, and as there is no cure for cancer yet, spotting the symptoms is important. One of the possible indicators of the disease is through another condition, according to a new report.
Express reports that jaundice may also be a possible symptom of prostate cancer among men. Jaundice is referred to as having a yellowish tinge in the skin, as well as the whites of the eyes. This is caused by issues with the liver, and this condition would mean that the cancer has already progressed and spread towards the liver, where there may be some problems with the bile duct or large parts of the liver that have already been affected.
Jaundice is not the only indication that the cancer has already affected the liver. Other indicators include a pain on the right side of the body, nausea, loss of appetite, weight loss, itchy skin, as well as a swollen tummy.
Another possible indicator of prostate cancer is found in the urine. Express also reports that seeing a pink, red, or brownish-red color in the urine may be a symptom of prostate cancer. This would mean that there is blood. The same applies if there is blood in the semen, as the prostate is responsible for the production of semen, the fluid that is carrying the sperm. According to Cancer News Today, finding blood in the urine is also known as hematuria, and it can indicate that the prostate cancer has progressed.
However, because these are merely symptoms, there is a big chance that it may indicate other conditions that are not as severe as prostate cancer. Still, in case these are seen, then it is highly advised to consult a doctor to get a proper diagnosis and treatment. The earlier this is detected, the more successful treatment will be.
Prostate cancer mainly affects men above the age of 50, and the usual time of diagnosis between men is from 65 to 69. The risk of developing prostate cancer increases among men if there is a family history of either prostate or breast cancer.


Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds
FDA Weighs Safety Standards for Psychedelic Therapies
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak
U.S. Issues Cuba Health Alert as Illnesses Rise
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
3 clinical-grade skincare creams you really shouldn’t buy online
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 



